Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Net Income (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Net Income for 4 consecutive years, with -$12.2 million as the latest value for Q3 2025.

  • Quarterly Net Income rose 80.87% to -$12.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$8.5 million through Dec 2025, up 92.9% year-over-year, with the annual reading at -$116.2 million for FY2011, 14.19% down from the prior year.
  • Net Income for Q3 2025 was -$12.2 million at Lexicon Pharmaceuticals, down from $3.7 million in the prior quarter.
  • The five-year high for Net Income was $3.7 million in Q2 2025, with the low at -$63.7 million in Q3 2024.